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Abstract
The number of the indirect methods for LDL-C estimation is growing. Our result support the
reliability of new Anandaraja's formula for low-density lipoprotein estimation from total cholesterol
and triglycerides.
Gazi et al [1] presented results of evaluation the accuracy
of various formulas for the calculation of low-density
lipoprotein cholesterol (LDL-C) levels – indirect methods
– in patients with the metabolic syndrome. LDL-C accord-
ing Friedewald's formula showed significant differences
from other formulas in the total cohort, as well as in
patients with metabolic syndrome. Different plasma lipid
and lipoprotein analytical techniques – direct methods,
however, yield results, which are highly correlated, yet sig-
nificantly different, too [2].
It is possible to supplement next calculation. Anandaraja
et al [3] published new formula for LDL-C estimation
from two other parameters, total cholesterol and triglycer-
ides, as substitution to well known Friedewald's formula.
Our team recently compared two methods of estimation
of low-density lipoprotein cholesterol, the direct Wako
method versus Friedewald's formula [4]. We studied over
10 000 consecutive patients with different diseases, from
mixed rural and urban Brazil population.
We re-counted our data with Anandaraja's formula. Main
results are expressed in Table 1. Direct LDL-C and LDL-C
calculated from Anandaraja's formula shows substantial
better correlation in both total population (r = 0,969) and
patients with triglyceride <350 mg/dl (r = 0,974) by com-
parison with calculated according to the Friedewald's for-
mula (r = 0,924 and r = 0,935).
In each very low-density lipoprotein particle secreted from
the liver, and therefore in each intermediate-density lipo-
protein, low-density lipoprotein and lipoprotein (a) par-
ticles, a single molecule of apolipoprotein B (apo B) is
present from the time of its assembly to its catabolism,
which does not exchange between lipoproteins. More
than 90% of apo B is in the low-density lipoprotein parti-
cles, and therefore, plasma total concentration of apo B
can be considered as a measure of the number of athero-
genic particles. New Anandaraja's equation takes into
account only total cholesterol and triglycerides. Some
authors recommend including apo B measurement as
acomponent of the standard lipoprotein measurements
performed to assess cardiovascular disease risk [5]. Contri-
bution of LDL-C calculation with help of measured apo B
is questionable. Apo B is real an independent risk factor.
In conclusion, LDL-C is the major indicator for initial clas-
sification of coronary heart disease risk status and lower-
ing its level is a primary goal of therapy. The NCEP
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Working Group on Lipoprotein Measurement recom-
mended the development of accurate direct low-density
lipoprotein cholesterol methods. All available direct
methods have yet limitations for general use. Our results
support the reliability of Anandaraja's formula as indirect
low-density lipoprotein cholesterol estimation – origi-
nally used in Indian population – in Brazil population,
too.
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Table 1: Low-density lipoprotein cholesterol level
Particulars Total population Patients with triglycerides
<350 mg/dl (3,94 mmol/l)
Total sample number 10 324 10 102
Direct low-density lipoprotein cholesterol (mg/dl; mmol/l) 116 ± 22 (2,99 ± 0,57) 115 ± 22 (2,97 ± 0,57)
Calculated low-density lipoprotein cholesterol (mg/dl; mmol/l)* 120 ± 24 (3,10 ± 0,62) 119 ± 23 (3,08 ± 0,59)
Calculated low-density lipoprotein cholesterol (mg/dl; mmol/l)† 115 ± 23 (2,97 ± 0,59) 114 ± 21 (2,95 ± 0,54)
Difference between direct low-density lipoprotein cholesterol and calculated low-density 
lipoprotein cholesterol (mg/dl)*
- 4 ± 16 - 4 ± 14
Difference between direct low-density lipoprotein cholesterol and calculated low-density 
lipoprotein cholesterol (mg/dl) †
1 ± 14 1 ± 14
Correlation coefficient between direct low-density lipoprotein cholesterol and calculated 
low-density lipoprotein cholesterol*
0,924 0,935
Correlation coefficient between direct low-density lipoprotein cholesterol and calculated 
low-density lipoprotein cholesterol†
0,969 0,974
All measurements are expressed in mg/dl (mmol/l) and results are presented as mean ± S.D. Pearson's correlation coefficient used. Direct LDL-C 
measured with Wako method – for details see Ref. [4].
* Calculated low-density lipoprotein cholesterol from Friedewald's formula
† Calculated low-density lipoprotein cholesterol from new Anandaraja's equation